IMiD-mediated degradation of IKZF1 and IKZF3 results in myeloma cell growth arrest as well as activation of T cells (180, 181), both of which may contribute to anti-myeloma effects of IMiDs. This evidence concerns the gene IKZF3 and plasma cell myeloma.